)
)
)
Akeylink Pharmaceuticals
Akeylink Biotechnology Co., Ltd. is a clinical-stage biopharmaceutical company focusing on the discovery and development of innovative small-molecule drugs for antiviral and liver diseases. Established in 2021 and headquartered in Shanghai, China, Akeylink is a wholly-owned subsidiary of Fujian Cosunter Pharmaceutical Co., Ltd. (广生堂), a publicly listed company on the Shenzhen Stock Exchange (ticker: 300436.SZ). The company maintains a pipeline of numerous proprietary oral small-molecule assets in clinical development, with a strategic emphasis on hepatitis B virus (HBV) functional cure, broad-spectrum antivirals, and liver-related diseases.
Address
ShanghaiShanghai
China
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)